← Eichor
Study identifier: NCT06659146 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Thermotherapy in Addition to SOC Palliative Radiotherapy

Condition: Head and Neck Squamous Cell Carcinoma · Cutaneous Squamous Cell Carcinoma · Breast Cancer Recurrent  ·  Sponsor: King's College London

PhaseNA
Planned participants60
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to investigate the efficacy and safety profile of superficial hyperthermia (wIRA) in addition to standard of care (SOC) palliative radiotherapy in patients with inoperable/incurable locally advanced or recurrent/metastatic HNSCC or cutaneous SCC superficial tumours not suitable for radical treatment. The investigators will assess the best objective response rate (ORR) of patients with Inoperable/incurable or recurrent/metastatic HNSCC or cSCC with superficial lesion(s) treated with the combination of superficial hyperthermia (wIRA) and palliative radiotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Anthony Kong  ·  44+2078486004  ·  Anthony.Kong@kcl.ac.uk

Taylor McKenzie  ·  44+2078486004  ·  taylor.mckenzie@kcl.ac.uk

Always discuss trial participation with your own doctor first.

Locations (2)

Guy's and St. Thomas NHS Foundation TrustLondon, United KingdomRecruiting
Guy's Cancer CentreLondon, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06659146